ESTRO 2024 - Abstract Book

S412

Brachytherapy - Urology

ESTRO 2024

G3 haematuria in the “3x11 Gy” group, and one with G3 urinary tract obstruction in the “2x13 Gy” group. During the whole follow-up, G1 –G2 erectile dysfunction was reported in 6.3% of patients in the “3x11 Gy” and in 12.9% - in the “2x13 Gy” group (p=0.1).

Conclusion:

HDR-BT monotherapy is an efficient treatment for localised prostate cancer in low- and intermediate-risk groups. Both “3x11 Gy” and “2x13 Gy” schedules have similar efficacy. However, the former seems to have a better toxicity profile. A prospective trial is needed to confirm these findings.

Keywords: intermediate risk, erectile dysfunction

References:

1. Armstrong, S., Brown, S., Stancliffe, M., Ostler, P., Hughes, R., Hoskin, P., & Alonzi, R. (2021). Single dose high-dose rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial. Radiotherapy and Oncology, 159, 67 – 74. https://doi.org/10.1016/j.radonc.2021.03.018 2. Corkum, M., Loblaw, A., Hasan, Y., Chung, H. T., Tseng, C. L., McGuffin, M., Cheung, P., Szumacher, E., Liu, S., Chu, W., Zhang, L., Mamedov, A., & Morton, G. (2021). Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiotherapy and Oncology, 156, 160 – 165. https://doi.org/10.1016/j.radonc.2020.12.021 3. Lane, J. A., Donovan, J. L., Young, G. J., Davis, M., Walsh, E. I., Avery, K. N. L., Blazeby, J. M., Mason, M. D., Martin, R. M., Peters, T. J., Turner, E. L., Wade, J., Bollina, P., Catto, J. W. F., Doherty, A., Gillatt, D., Gnanapragasam, V., Hughes, O., Kockelbergh, R., … Roberts, T. (2022). Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study). BJU International, 130(3), 370 – 380. https://doi.org/10.1111/bju.15739 4. Morton, G., McGuffin, M., Chung, H. T., Tseng, C. L., Helou, J., Ravi, A., Cheung, P., Szumacher, E., Liu, S., Chu, W., Zhang, L., Mamedov, A., & Loblaw, A. (2020). Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiotherapy and Oncology, 146, 90 – 96. https://doi.org/10.1016/j.radonc.2020.02.009 5. Strnad, V., Lotter, M., Kreppner, S., & Fietkau, R. (2022). Brachytherapy focal dose escalation using ultrasound based tissue characterization by patients with non-metastatic prostate cancer: Five-year results from single-center phase 2 trial. Brachytherapy, 21(4), 415 – 423. https://doi.org/10.1016/j.brachy.2022.02.003

1367

Digital Poster

Predictors of the risk of metastasis and death in prostate cancer treated with HDR boost